Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4

Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML). Nuclear factor E2-related factor 2 (Nrf2) plays a crucial role in tumor chemotherapy resistance. However, the potential mechanism of Nrf2 regulating DNA mismatch repair (MMR) pathway to mediate gene-instability...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2022-11, Vol.29 (11), p.1773-1790
Hauptverfasser:	Hu, Tianzhen, Pan, Chengyun, Zhang, Tianzhuo, Ni, Ming, Wang, Weili, Zhang, Siyu, Chen, Ying, Wang, Jishi, Fang, Qin
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/2 13/31 13/51 14/1 14/35 14/63 38/1 38/35 631/208/199 631/67/1990/283 Acute myeloid leukemia Biomedical and Life Sciences Biomedicine Cell Line, Tumor Chemoresistance Chemotherapy Cytarabine Cytarabine - pharmacology Cytarabine - therapeutic use DNA biosynthesis DNA repair Drug resistance Drug Resistance, Neoplasm - genetics Gene Expression Gene Therapy Genomic instability Humans Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Mismatch repair NF-E2-Related Factor 2 - genetics NF-E2-Related Factor 2 - metabolism NF-kappa B - metabolism NF-κB protein Replication Reporter gene Signal transduction Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!